Luminex Corporation To Host Investor Event December 11, 2012

        






Luminex Corporation To Host Investor Event December 11, 2012

AUSTIN, Texas, Nov. 27, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) will host an investor event in New York City on Tuesday, December 11, 2012 beginning at 8am ET, as previously announced on its third quarter financial results conference call.  

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Patrick J. Balthrop, president and chief executive officer, and other members of the executive management team will provide insight into the company's long-term strategic plans with a focus on its molecular diagnostic product pipeline.   

Advanced registration is required and attendance will be limited to those registered. To register, please contact Matthew Scalo, Senior Director of Investor Relations. Breakfast will be served beginning at 7am ET.

The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived on the website using the 'replay' link.

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP® open-architecture, multi-analyte platform and our MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies.  We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.  For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.

Contacts:	Matthew Scalo
	Sr. Director of Investor Relations
	512-219-8020
	[e-mail]

 

SOURCE Luminex Corporation

Copyright 2012 PR Newswire